Guillain-Barré Syndrome:

Pathogenesis, Clinical Features, Diagnostic Standards and Therapy

Suyash Ingle*, Abhilasha Waghmode, Gayatri Kasture, Manuja Ugade, Mehak Shaikh

Dept of Pharmaceutical Quality Assurance,

Gandhi Natha Rangji college of Pharmacy, Solapur, Maharashtra, India-413002.

*Corresponding Author E-mail: suyashingle1806@gmail.com

ABSTRACT:

Guillain-Barré syndrome (GBS) is an extremely uncommon immune-mediated condition that primarily affects previously healthy people and is characterised by progressive muscle weakness and peripheral nerve system demyelination. It is severe enough to require hospitalization for treatment and typically manifests as ascending paralysis. GBS affects 1.1 to 1.8 out of every 100,000 people annually, and the frequency rises with age. Acute Inflammatory Demyelinating Polyneuropathy (AIDP), Acute Motor Axonal Neuropathy (AMAN), Acute Motor and Sensory Axonal Neuropathy (AMSAN), and Miller Fisher Syndrome (MFS) are all included in the diverse clinical spectrum of GBS. Patients of all ages often experience the disease's hallmark, symmetrical limb weakness, which develops quickly and lasts for days to four weeks. Additionally, the majority of patients have sensory issues including tingling or a lackluster sensation. Acute flaccid paralysis is now most frequently caused by GBS in affluent nations. GBS is still a serious illness even with better diagnosis and care. Effective therapies include plasma exchange and intravenous immunoglobulin, although supportive care both during and after hospitalization is also highly important. In this article we review the current understanding of pathophysiology and clinical features of GBS and its variants.

KEYWORDS: Guillain-Barre syndrome (GBS), AIDP, AMAN, AMSAN, MFS, Intravenous immunoglobulin, Ganglioside antibodies, Dignosis and treatment.

INTRODUCTION:

Guillain-Barré syndrome first became known over a century ago when Guillain-Barré and Strohl described two different instances of acute flaccid paralysis with albumino-cytological dissociation. Guillain-Barré syndrome (GBS) is a curable but possibly fatal illness.

GBS offers important insights into the causes of peripheral inflammation of nerves and is currently one of the most capable understood neuroinflammatory illnesses. The most widespread cause of acute or subacute localized paralysis is Guillain-Barre Syndrome, which was once second only to polio in terms of currency. Guillain-Barre syndrome is also known as acute inflammatory demyelinating polyneuropathy (AIDP) or Landry-Guillain-Barre-Strohl syndrome. The estimated yearly incidence worldwide is between 0.6 and 2.4 cases per 100,000 people. The likelihood of injury is nearly 1.5 times higher for men than for women. Acute inflammatory demyelinating polyradiculoneuropathy (AIDP) is the most common subtype in North America and Europe, making up 90% of all cases.

The most typical reason for neuromuscular paralysis is Guillain-Barre syndrome. There are various subtypes of Guillain-Barre syndrome. Acute inflammatory demyelinating polyneuropathy (AIDP) and acute motor axonal neuropathy (AMAN)². The most common signs include paralysis and areflexia, or weakening of the limbs. A syndrome called Miller Fisher Syndrome corresponds to One of the most prevalent ailments is Miller Fisher Syndrome, which involves acute motor axonal neuropathy and acute inflammatory demyelinating polyneuropathy. The sickness is immune-mediated. Symptoms of ataxia and areflexia can be observed in numerous distinct disorders. This disease is managed with plasma exchange and immunoglobulin.

In the first week of the illness, normal CSF protein is typical and does not rule out GBS. In the second week following the onset of symptoms, it may be normal or only slightly raised. A higher WCC should raise suspicions of granulomatous inflammatory diseases such as sarcoidosis, haematological malignancy, or infections like HIV or Lyme. Importantly, CSF should be obtained before beginning IVIg medication, which usually increases WCC and CSF protein. Weeks after the commencement of the disease, nerve conduction studies and electromyography are usually never normal. They may be normal in the early days or reveal in excitable nerves, which indicates serious nerve damage.

The pathogenesis of GBS (Guillain-Barré syndrome):

Axonal destruction and/or demyelination result from the body's immune system attacking peripheral nerves and nerve roots in GBS, an immunological-mediated illness. Most of the time, an antecedent infection (such Campylobacter jejuni or CMV) or, in rare cases, vaccination, starts the process.

1. Molecular Mimicry:

The Crucial Process Molecular mimicry, in which immune responses against microbial antigens cross-react with nerve gangliosides (glycolipids prevalent in peripheral nerves), is the main mechanism underlying GBS.

Targets of Gangliosides: Most prevalent in motor axonal types such as AMAN are GM1, GD1a, and GQ1b. Miller Fisher Syndrome is closely linked to GQ1b.

The mechanism Bacterial lipooligosaccharides (LOS) imitate human gangliosides upon infection (e.g., C. jejuni). Anti-ganglioside antibodies (IgG/IgM) are produced by the immune system and attach to neuronal membranes, triggering: C3a, C5a, and membrane attack complex [MAC] are examples of complement cascades. Macrophage infiltration results in nerve damage, such as axonal degeneration or demyelination.

2. Subtype-Specific Mechanisms:

The pathophysiology differs depending on the subtype of GBS:

A. Demyelinating polyneuropathy with acute inflammation (AIDP), most prevalent (almost 90% of cases) in Western nations. The main pathology Peripheral nerve demyelination caused by T cells and macrophages. Myelin sheaths and Schwann cells are the targets of inflammation. As demonstrated by electrophysiology, nerve conduction is slowed.

B. Acute Motor Axonal Neuropathy (AMAN), associated with C. jejuni, is more prevalent in Asia and Latin America. The main pathology Motor axons at Ranvier nodes are bound by IgG anti-ganglioside antibodies (GM1/GD1a).

MAC deposition → axonal damage (affected primary motor fibers) → complement activation. Axonal degeneration without demyelination and little inflammation.

C. Miller Fisher Syndrome (MFS): The three symptoms of Miller Fisher Syndrome are areflexia, ataxia, and ophthalmoplegia. Anti-GQ1b antibodies target sensory ganglia and cranial nerves III, IV, and VI.

3. Secondary Mechanism of Nerve Injury:

Membrane attack complex (MAC) development compromises nerve integrity, which is one of the secondary mechanisms of nerve injury complement activation. Mediators of Inflammation: TNF-α and IL-17 are cytokines that exacerbate nerve injury. The blood-nerve barrier is disrupted by matrix Dysautonomia: Autonomic ganglia may be impacted by autoantibodies.

4. Role of Antecedent Infections:

Infection	Associated GBS Subtype	Target Ganglioside
Campylobacter jejuni	AMAN, AMSAN	GM1, GD1a
Cytomegalo virus (CMV)	AIDP	GM2, others
Epstein-Barr virus (EBV)	AIDP	Unknown
Zika virus	AIDP/AMAN	GD1a, others

GBS defence mechanisms against the immune system. GBS expresses a variety of components that improve its survival in the host and enable it to elude the immune system. GBS presents as "self" to the immune system thanks to the sialic acid capsule and fibrin fragments that coat its surface and are broken down by CspA. Additionally, the capsule prevents phagocyte identification and C3 deposition. By binding or cleaving complement components, sialic acid found in the capsule, protein, ScpB, CIP, and BibA inhibits the complement system. In order to prevent immunological activation, the GBS-protein also attaches to the Fc region of IgA1. While PilB, PBP1a, and proteins produced by the dlt operon help to fend against antimicrobial peptides, HylB and CspA block or cleave cytokines. The DNA matrix of neutrophil extracellular traps is broken down by NucA. Hemolysin/cytolysin (-h/c) and GAPDH help trigger phagocyte apoptosis, while glutathione, carotenoid pigment, and SodA all support defence against reactive oxygen species.

Clinical Features:

Acute, quickly developing flaccid paralysis of the arms and legs, as well as missing or diminished deep reflexes of the tendons, are the hallmarks of GBS. There may or may not be a sensory disruption. According to extensive research, patients frequently attain their lowest level of incapacity around ten to fourteen days, and symptoms hardly ever worsen for longer than 4 weeks. A characteristic of GBS is CSF albuminocytological dissociation, which is characterised by a large protein level and an adequate white cell count (WCC). When combined with an elevated CSF/serum albumin quotient (Qalb), this suggests that the blood–nerve barrier in the affected nerve roots has been disrupted, allowing proteins to penetrate into the subarachnoid space via leaky vessels.

Diagnostic Standards:

Diagnostic Tests-

1. Lumbar Puncture (CSF Analysis): Albuminocytologic dissociation (↑ protein, normal WBC count).

2. Nerve Conduction Studies (NCS): Slowed conduction (AIDP) or axonal loss (AMAN/AMSAN).

3. Serum Antibodies: Anti-ganglioside antibodies (e.g., anti-GM1, GQ1b in MFS).

Therapy and Results:

Thirty-two (88.8%) of the 36 patients were given intravenous immunoglobulin (IVIG). Three (8.3%) did not receive any treatment since they were either in the recovery phase or had very little weakness, while one (2.7%) underwent plasmapheresis. In 3 cases (8.3%), repeated IV IG doses were necessary. At discharge and at 1, 3, 6, and 12 months, the outcome was evaluated. Of the cases, 32 (88.8%) were able to walk with or without assistance at 3 months, 33 (91.6%) recovered completely at 6 months, 2 (5.5%) recovered at 12 months, and 1 (2.7%) was bedridden. At 12 months, 35 people had fully recovered (97.2%).

CONCLUSION:

Guillain-Barré Syndrome remains a clinically significant and potentially life-threatening autoimmune neuropathy, characterized by rapidly progressive muscle weakness and areflexia. Despite advances in diagnostic tools and therapeutic interventions, early recognition and prompt initiation of treatment—typically with intravenous immunoglobulin (IVIG) or plasmapheresis—are critical to improving outcomes. Recent research into the immunopathogenesis of GBS has enhanced our understanding of the disease, particularly regarding the role of molecular mimicry and the diversity of clinical variants. Although most patients experience substantial recovery, a subset continues to face long-term disability, underscoring the need for improved prognostic markers and rehabilitation strategies. Future directions include the identification of novel biomarkers, personalized treatment approaches, and development of targeted immunotherapies. Continued multidisciplinary research efforts are essential to optimize patient care and to reduce the global burden of this complex neurological disorder. Investigations persist in revealing improved treatments and comprehending catalysts.

REFERENCE:

1. Guillain-Barré syndrome: clinical profile and management. GMS German Medical Science. 2015; 13.2.

2. Dhadke SV, Dhadke VN, Bangar SS, Korade MB. Clinical profile of Guillain-Barre syndrome. The Journal of the Association of Physicians of India. 2013; 61(3):168-7

3. Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain J Neurol 1995; 118(Pt 3):597-605. doi:10.1093/brain/118.3.597

4. Derksen A, Ritter C, Athar P, et al. Sural sparing pattern discriminates Guillain-Barré syndrome from its mimics. Muscle Nerve 2014; 50(5):780-784. doi:10.1002/mus.24226

5. Uncini A, Susuki K, Yuki N. Nodo-paranodopathy:beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies. Clin Neurophysiol2013; 124(10):1928-1934. doi:10.1016/j.clinph.2013.03.025

6. Inoue N, Ichimura H, Goto S, Hashimoto Y, Ushio Y. MR imaging findings of spinal posterior column involvement in a case of Miller Fisher syndrome. AJNR Am J Neuroradiol 2004; 25(4):645-648.

7. Che Y, Qiu J, Jin T, et al. Circulating memory T follicular helper subsets, Tfh2 and Tfh17, participate in the pathogenesis of Guillain-Barré syndrome. Sci Rep 2016; 6: 20963. doi:10.1038/srep20963

8. Walgaard C, Lingsma HF, Ruts L, et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol 2010; 67(6):781-787.doi:10.1002/ana.21976

9. Burakgazi AZ, Höke A. Respiratory muscle weakness in peripheral neuropathies. J Peripher Nerv Syst 2010; 15(4):307-313.

10. Korinthenberg R, Schessl J, Kirschner J, Mönting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics 2005; 116(1):8-14. doi:10.1542/peds.2004-1324

11. Overell JR, Hsieh ST, Odaka M, Yuki N, Willison HJ. Treatment for Fisher syndrome, Bickerstaff’s brainstem encephalitis and related disorders. Cochrane Database Syst Rev 2007; 2007(1): CD004761.doi:10.1002/14651858.CD004761.pub2

12. Hiraga A, Mori M, Ogawara K, et al. Recovery patterns and long term prognosis for axonal Guillain–Barré syndrome. J Neurol Neurosurg Psychiatry 2005; 76(5):719-722.doi:10.1136/jnnp.2004.051136

13. Walteros DM, Soares J, Styczynski AR, et al. Long-term outcomes of Guillain-Barré syndrome possibly associated with Zika virus infection. PLOS ONE 2019; 14(8):e0220049. doi:10.1371/journal.pone.0220049

14. Sepehrar M, Khorram H, Raja SK, Kothandapani S, Noroozpour Z, Sham MA, Prasad N, Sunny SP, Mohammed MD. Guillain-Barré syndrome: clinical profile and management. GMS German Medical Science. 2015; 13.

15. Omkar A. Devade, Rohan D. Londhe, Nikhil M. Meshram. Review on Spinal Muscular Atrophy. Research Journal of Pharmacology and Pharmacodynamics.2022; 14(4):246-2.

16. Alter M. The epidemiology of Guillain-Barré syndrome. Ann Neurol.1990; 27(S1):S7http://dx.doi.org/10.1002/ana.410270704; PMid:2194431

17. S Sreeni, Nafiya Muhammed Zackariah, Lakshmi R. A Case Report: Morvan’s Syndrome. Research J. Pharm. and Tech. 2017; 10(4): 1174-1178

18. Orlikowski D, Prigent H, Sharshar T, Lofaso F, Raphael JC. Respiratory dysfunction Guillain-Barré Syndrome.Neurocrit Care. 2004; 1(4):415-22. http://dx.doi.org/10.1385/NCC:1:4:415.

19. Suman Sharma, Deepinder Singh, Ashima Katyal, Paramjeet S. Gill, Surender Jangra, Bhupender Bhardwaj, Usha Bhocal. Evaluation of outcome of disease in COVID-19 patients with Comorbidities: An experience from a Tertiary Care Center in North India. Research Journal of Pharmacy and Technology. 2024; 17(1):31-6

Received on 19.05.2025 Revised on 16.09.2025

Accepted on 03.12.2025 Published on 22.01.2026

Available online from January 29, 2026

Asian J. Pharm. Res. 2026; 16(1):97-100.

DOI: 10.52711/2231-5691.2026.00013

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.